AAO | videos

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.

Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.

At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

At the 2022 American Academy of Ophthalmology meeting, Dr Philip Dockery, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

Dr Mark H. Blecher dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.

Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr Raymond Douglas discusses real-world adherence to teprotumumab as a treatment for thyroid eye disease.

Dr Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DMO resolution.

Dr Preeya Gupta walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

Dr Lisa Nijm discusses how utilising a dexamethasone intracanalicular insert after cataract surgery saves time for practices.

Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.

At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Dr Mohamed Abou Shousha discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Dr Sunir J. Garg speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

Dr Ajay Kuriyan discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular oedema in clinical trial setting."

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.